Zhejiang Tianyu Pharmaceutical Co Ltd (300702) - Total Assets

Latest as of September 2025: CN¥6.56 Billion CNY ≈ $960.51 Million USD

Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) holds total assets worth CN¥6.56 Billion CNY (≈ $960.51 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 300702 book value for net asset value and shareholders' equity analysis.

Zhejiang Tianyu Pharmaceutical Co Ltd - Total Assets Trend (2013–2024)

This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Zhejiang Tianyu Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Zhejiang Tianyu Pharmaceutical Co Ltd's total assets of CN¥6.56 Billion consist of 47.6% current assets and 52.4% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 9.0%
Accounts Receivable CN¥596.24 Million 9.1%
Inventory CN¥1.88 Billion 28.6%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥464.72 Million 7.1%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2013–2024)

This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Zhejiang Tianyu Pharmaceutical Co Ltd.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Zhejiang Tianyu Pharmaceutical Co Ltd's current assets represent 47.6% of total assets in 2024, a decrease from 52.0% in 2013.
  • Cash Position: Cash and equivalents constituted 9.0% of total assets in 2024, down from 11.3% in 2013.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 5.0% in 2013.
  • Asset Diversification: The largest asset category is inventory at 28.6% of total assets.

Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Zhejiang Tianyu Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Zhejiang Tianyu Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.19 1.15 2.37
Quick Ratio 0.45 0.43 1.56
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥473.35 Million CN¥390.12 Million CN¥1.68 Billion

Zhejiang Tianyu Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Zhejiang Tianyu Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.37
Latest Market Cap to Assets Ratio 0.16
Asset Growth Rate (YoY) 3.8%
Total Assets CN¥6.58 Billion
Market Capitalization $1.07 Billion USD

Valuation Analysis

Below Book Valuation: The market values Zhejiang Tianyu Pharmaceutical Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Zhejiang Tianyu Pharmaceutical Co Ltd's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual total assets of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2024.

Year Total Assets Change
2024-12-31 CN¥6.58 Billion
≈ $962.65 Million
+3.79%
2023-12-31 CN¥6.34 Billion
≈ $927.47 Million
-1.21%
2022-12-31 CN¥6.42 Billion
≈ $938.83 Million
+10.60%
2021-12-31 CN¥5.80 Billion
≈ $848.81 Million
+18.63%
2020-12-31 CN¥4.89 Billion
≈ $715.50 Million
+72.15%
2019-12-31 CN¥2.84 Billion
≈ $415.61 Million
+8.02%
2018-12-31 CN¥2.63 Billion
≈ $384.75 Million
+24.81%
2017-12-31 CN¥2.11 Billion
≈ $308.27 Million
+39.05%
2016-12-31 CN¥1.52 Billion
≈ $221.70 Million
+14.23%
2015-12-31 CN¥1.33 Billion
≈ $194.09 Million
+22.26%
2014-12-31 CN¥1.08 Billion
≈ $158.75 Million
+11.64%
2013-12-31 CN¥971.79 Million
≈ $142.20 Million
--

About Zhejiang Tianyu Pharmaceutical Co Ltd

SHE:300702 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.07 Billion
CN¥7.34 Billion CNY
Market Cap Rank
#8796 Global
#2320 in China
Share Price
CN¥21.09
Change (1 day)
-1.03%
52-Week Range
CN¥20.38 - CN¥29.77
All Time High
CN¥69.67
About

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical … Read more